| Literature DB >> 27488530 |
Nicole D Facompre1, Kayla M Harmeyer1, Xavier Sole2, Sheheryar Kabraji2, Zachary Belden1, Varun Sahu1, Kelly Whelan3, Koji Tanaka3, Gregory S Weinstein1, Kathleen T Montone4, Alexander Roesch5, Phyllis A Gimotty6, Meenhard Herlyn7, Anil K Rustgi3, Hiroshi Nakagawa3, Sridhar Ramaswamy2, Devraj Basu8.
Abstract
The degree of heterogeneity among cancer stem cells (CSC) remains ill-defined and may hinder effective anti-CSC therapy. Evaluation of oral cancers for such heterogeneity identified two compartments within the CSC pool. One compartment was detected using a reporter for expression of the H3K4me3 demethylase JARID1B to isolate a JARID1B(high) fraction of cells with stem cell-like function. JARID1B(high) cells expressed oral CSC markers including CD44 and ALDH1 and showed increased PI3K pathway activation. They were distinguished from a fraction in a G0-like cell-cycle state characterized by low reactive oxygen species and suppressed PI3K/AKT signaling. G0-like cells lacked conventional CSC markers but were primed to acquire stem cell-like function by upregulating JARID1B, which directly mediated transition to a state expressing known oral CSC markers. The transition was regulated by PI3K signals acting upstream of JARID1B expression, resulting in PI3K inhibition depleting JARID1B(high) cells but expanding the G0-like subset. These findings define a novel developmental relationship between two cell phenotypes that may jointly contribute to CSC maintenance. Expansion of the G0-like subset during targeted depletion of JARID1B(high) cells implicates it as a candidate therapeutic target within the oral CSC pool. Cancer Res; 76(18); 5538-49. ©2016 AACR. ©2016 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27488530 PMCID: PMC5026599 DOI: 10.1158/0008-5472.CAN-15-3377
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701